The Record · Denmark
Denmark. Every lock, every score.
5 forecasts on Denmark, each committed to a public criterion before the outcome was known and scored against that exact criterion afterwards. 1 resolved — 1 hit, 0 miss.
November 20262 locks resolving
| Ref | The locked call | Resolves | Status |
|---|---|---|---|
| P-164 | Maersk Q3 2026 underlying EBITDAMaersk Q3 2026 underlying EBITDA ≥US$2.2bn (~27% below Q2) — ~0.92 | 5 Nov 2026locked 13 Aug 2026 | Locked |
| P-186 | Vestas FY2026 margin floorVestas keeps FY2026 EBIT margin floor ≥7% at Q3 (raised from 6-8%) — ~0.88 | 11 Nov 2026locked 13 Aug 2026 | Locked |
February 20272 locks resolving
| Ref | The locked call | Resolves | Status |
|---|---|---|---|
| P-276 | DSV FY2026 EBIT before special itemsDSV FY2026 EBIT BEFORE SPECIAL ITEMS >= DKK 22.5bn (guidance narrowed UP to DKK 23.5-25.5bn; forwarder, opposite freight exposure to P-237 Maersk) — ~0.91 | 4 Feb 2027locked 2 Sep 2026 | Locked |
| P-237 | Maersk FY2026 underlying EBITDAMaersk FY2026 UNDERLYING EBITDA >= USD 10.0bn (guidance raised to USD 10.5-12.5bn; underlying NOT reported EBITDA) — ~0.89 | 5 Feb 2027locked 29 Aug 2026 | Locked |
August 20261 lock resolved
| Ref | The locked call | Resolves | Status |
|---|---|---|---|
| P-92 | Novo Nordisk Wegovy Q2 2026Novo Wegovy franchise sales grow Q2 > Q1 2026 — ~0.80HIT - Wegovy franchise grew Q2>Q1: Wegovy pill DKK 2,256M -> 3,141M (+885M QoQ); Novo beat on Wegovy and raised FY guidance, obesity-care sales up. Pill-driven; the injectable faced YoY price pressure. | 5 Aug 2026locked 24 Jun 2026 | Hit |